ADMA Biologics, Inc.ADMANASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank28
3Y CAGR-36.2%
5Y CAGR-0.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-36.2%/yr
vs -23.1%/yr prior
5Y CAGR
-0.1%/yr
Recent deceleration
Acceleration
-13.1pp
Decelerating
Percentile
P28
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.01% |
| Q3 2025 | 3.75% |
| Q2 2025 | -7.75% |
| Q1 2025 | 3.27% |
| Q4 2024 | 25.63% |
| Q3 2024 | 11.75% |
| Q2 2024 | 6.20% |
| Q1 2024 | 0.67% |
| Q4 2023 | 5.49% |
| Q3 2023 | 3.35% |
| Q2 2023 | -1.82% |
| Q1 2023 | 4.44% |
| Q4 2022 | 7.77% |
| Q3 2022 | 7.71% |
| Q2 2022 | -12.62% |
| Q1 2022 | 17.11% |
| Q4 2021 | 9.05% |
| Q3 2021 | 2.77% |
| Q2 2021 | 4.03% |
| Q1 2021 | 7.89% |
| Q4 2020 | 2.03% |
| Q3 2020 | 4.75% |
| Q2 2020 | 9.71% |
| Q1 2020 | 12.80% |
| Q4 2019 | -2.29% |
| Q3 2019 | 18.26% |
| Q2 2019 | 8.77% |
| Q1 2019 | -21.58% |
| Q4 2018 | 33.23% |
| Q3 2018 | 6.97% |
| Q2 2018 | 0.04% |
| Q1 2018 | -3.46% |
| Q4 2017 | 23.57% |
| Q3 2017 | -5.41% |
| Q2 2017 | 3.70% |
| Q1 2017 | 30.27% |
| Q4 2016 | 84.56% |
| Q3 2016 | 3.19% |
| Q2 2016 | 0.95% |
| Q1 2016 | -9.37% |